Thus, we investigated whether CuB inhibits pancreatic cancer cell growth by modulating EGFR and its downstream signaling targets and tested whether CuB in combination with downstream EGFR signaling enhances its therapeutic efficacy. This evidence concerns the gene EGFR and familial pancreatic carcinoma.